Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers

Fig. 5

Spearman’s rank correlation analysis of anti-cardiolipin (aCL) IgG (a), aCL IgM (b), anti-beta 2 glycoprotein I (aß2GPI) IgG (c), and aß2GPI IgM (d) quantitative testing. Antiphospholipid antibodies were determined in 61 patients with antiphospholipid syndrome (APS) and 146 controls by line immunoassay (LIA) and enzyme-linked immunosorbent assay (ELISA). The following correlation coefficients (ρ) were obtained for aCL IgG and IgM, and aß2GPI IgG and IgM quantitative testing by LIA and ELISA (aCL IgG: ρ = 0.737 95 % CI 0.657, 0.801; aCL IgM: ρ = 0.593 95 % CI 0.482, 0.686; aß2GPI IgG: ρ = 0.774 95 % CI 0.702, 0.830; aß2GPI IgM: ρ = 0.566 95 % CI 0.449, 0.663, respectively; p < 0.001). aPL+ asymptomatic patients with autoantibodies to phospholipids, IDC infectious diseases controls, OAPS obstetric antiphospholipid syndrome, PAPS primary antiphospholipid syndrome, SAPS secondary antiphospholipid syndrome, VDRL+ Venereal Disease Research Laboratory test positive, OD optical density

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us